Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study

BACKGROUND: The NIBIT-MESO-1 study demonstrated the efficacy and safety of tremelimumab combined with durvalumab in patient with unresectable mesothelioma followed up for a median of 52 months [IQR 49–53]. Here, we report 4-year survival and outcomes after retreatment, and the role of tumour mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Calabrò, Luana, Rossi, Giulia, Morra, Aldo, Rosati, Claudio, Cutaia, Ornella, Daffinà, Maria Grazia, Altomonte, Maresa, Di Giacomo, Anna Maria, Casula, Milena, Fazio, Carolina, Palmieri, Giuseppe, Giannarelli, Diana, Covre, Alessia, Maio, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765708/
https://www.ncbi.nlm.nih.gov/pubmed/33844995
http://dx.doi.org/10.1016/S2213-2600(21)00043-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765708/
https://www.ncbi.nlm.nih.gov/pubmed/33844995
http://dx.doi.org/10.1016/S2213-2600(21)00043-6

Ejemplares similares